Cargando…
Folate-PEG Conjugates of a Far-Red Light-Activatable Paclitaxel Prodrug to Improve Selectivity toward Folate Receptor-Positive Cancer Cells
[Image: see text] We recently demonstrated the far-red light-activatable prodrug of paclitaxel (PTX), Pc-(L-PTX)(2). Upon illumination with a 690 nm laser, Pc-(L-PTX)(2) showed combinational cell killing from rapid photodynamic therapy damage by singlet oxygen, followed by sustained chemotherapy eff...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2017
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5664141/ https://www.ncbi.nlm.nih.gov/pubmed/29104951 http://dx.doi.org/10.1021/acsomega.7b01105 |
_version_ | 1783274948205215744 |
---|---|
author | Thapa, Pritam Li, Mengjie Karki, Radha Bio, Moses Rajaputra, Pallavi Nkepang, Gregory Woo, Sukyung You, Youngjae |
author_facet | Thapa, Pritam Li, Mengjie Karki, Radha Bio, Moses Rajaputra, Pallavi Nkepang, Gregory Woo, Sukyung You, Youngjae |
author_sort | Thapa, Pritam |
collection | PubMed |
description | [Image: see text] We recently demonstrated the far-red light-activatable prodrug of paclitaxel (PTX), Pc-(L-PTX)(2). Upon illumination with a 690 nm laser, Pc-(L-PTX)(2) showed combinational cell killing from rapid photodynamic therapy damage by singlet oxygen, followed by sustained chemotherapy effects from locally released PTX. However, its high lipophilicity (log D(7.4) > 3.1) caused aggregation in aqueous solutions and has nonselectivity toward cancer cells. To solve these important problems, we prepared folic acid (FA)-conjugated and photoactivatable prodrugs of PTX with a polyethylene glycol (PEG) spacer of various chain lengths: FA-PEG(n)-Pc-L-PTX [n = 0 (0k, 5), ∼23 (1k, 7a), ∼45 (2k, 7b), ∼80 (3.5k, 7c), or ∼114 (5k, 7d)]. The PEGylated prodrugs 7a–d had a much improved hydrophilicity compared with the non-PEGylated prodrug, Pc-(L-PTX)(2). As the PEG length increased, the hydrophilicity of the prodrug increased (log D(7.4) values: 1.28, 0.09, −0.24, and −0.59 for 1k, 2k, 3.5k, and 5k PEG prodrugs, respectively). Fluorescence spectral data suggested that the PEGylated prodrugs had good solubility in the culture medium at lower concentrations (<1–2 μM), but showed fluorescence quenching due to limited solubility at higher concentrations (>2 μM). Dynamic light scattering indicated that all of the prodrugs formed nanosized particles in both phosphate-buffered saline and culture medium at a concentration of 5 μM. The PEG length affected both nonspecific and folate receptor (FR)-mediated uptake of the prodrugs. The enhanced cellular uptake was observed for the prodrugs with medium-sized PEGs (1k, 2k, or 3.5k) in FR-positive SKOV-3 cells, but not for the prodrugs with no PEG or with the longest PEG (5k), which suggests the optimal range of PEG length around 1k–3.5k for effective uptake of our prodrug system. Consistent with the cellular uptake pattern, medium-sized PEGylated prodrugs showed more potent phototoxic activity (IC(50s), ∼130 nM) than prodrugs with no PEG or the longest PEG (IC(50), ∼400 nM). In conclusion, we have developed far-red light-activatable prodrugs with improved water solubility and FR-targeting properties compared with the nontargeted prodrug. |
format | Online Article Text |
id | pubmed-5664141 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | American Chemical Society |
record_format | MEDLINE/PubMed |
spelling | pubmed-56641412017-11-02 Folate-PEG Conjugates of a Far-Red Light-Activatable Paclitaxel Prodrug to Improve Selectivity toward Folate Receptor-Positive Cancer Cells Thapa, Pritam Li, Mengjie Karki, Radha Bio, Moses Rajaputra, Pallavi Nkepang, Gregory Woo, Sukyung You, Youngjae ACS Omega [Image: see text] We recently demonstrated the far-red light-activatable prodrug of paclitaxel (PTX), Pc-(L-PTX)(2). Upon illumination with a 690 nm laser, Pc-(L-PTX)(2) showed combinational cell killing from rapid photodynamic therapy damage by singlet oxygen, followed by sustained chemotherapy effects from locally released PTX. However, its high lipophilicity (log D(7.4) > 3.1) caused aggregation in aqueous solutions and has nonselectivity toward cancer cells. To solve these important problems, we prepared folic acid (FA)-conjugated and photoactivatable prodrugs of PTX with a polyethylene glycol (PEG) spacer of various chain lengths: FA-PEG(n)-Pc-L-PTX [n = 0 (0k, 5), ∼23 (1k, 7a), ∼45 (2k, 7b), ∼80 (3.5k, 7c), or ∼114 (5k, 7d)]. The PEGylated prodrugs 7a–d had a much improved hydrophilicity compared with the non-PEGylated prodrug, Pc-(L-PTX)(2). As the PEG length increased, the hydrophilicity of the prodrug increased (log D(7.4) values: 1.28, 0.09, −0.24, and −0.59 for 1k, 2k, 3.5k, and 5k PEG prodrugs, respectively). Fluorescence spectral data suggested that the PEGylated prodrugs had good solubility in the culture medium at lower concentrations (<1–2 μM), but showed fluorescence quenching due to limited solubility at higher concentrations (>2 μM). Dynamic light scattering indicated that all of the prodrugs formed nanosized particles in both phosphate-buffered saline and culture medium at a concentration of 5 μM. The PEG length affected both nonspecific and folate receptor (FR)-mediated uptake of the prodrugs. The enhanced cellular uptake was observed for the prodrugs with medium-sized PEGs (1k, 2k, or 3.5k) in FR-positive SKOV-3 cells, but not for the prodrugs with no PEG or with the longest PEG (5k), which suggests the optimal range of PEG length around 1k–3.5k for effective uptake of our prodrug system. Consistent with the cellular uptake pattern, medium-sized PEGylated prodrugs showed more potent phototoxic activity (IC(50s), ∼130 nM) than prodrugs with no PEG or the longest PEG (IC(50), ∼400 nM). In conclusion, we have developed far-red light-activatable prodrugs with improved water solubility and FR-targeting properties compared with the nontargeted prodrug. American Chemical Society 2017-10-04 /pmc/articles/PMC5664141/ /pubmed/29104951 http://dx.doi.org/10.1021/acsomega.7b01105 Text en Copyright © 2017 American Chemical Society This is an open access article published under an ACS AuthorChoice License (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html) , which permits copying and redistribution of the article or any adaptations for non-commercial purposes. |
spellingShingle | Thapa, Pritam Li, Mengjie Karki, Radha Bio, Moses Rajaputra, Pallavi Nkepang, Gregory Woo, Sukyung You, Youngjae Folate-PEG Conjugates of a Far-Red Light-Activatable Paclitaxel Prodrug to Improve Selectivity toward Folate Receptor-Positive Cancer Cells |
title | Folate-PEG Conjugates of a Far-Red Light-Activatable
Paclitaxel Prodrug to Improve Selectivity toward Folate Receptor-Positive
Cancer Cells |
title_full | Folate-PEG Conjugates of a Far-Red Light-Activatable
Paclitaxel Prodrug to Improve Selectivity toward Folate Receptor-Positive
Cancer Cells |
title_fullStr | Folate-PEG Conjugates of a Far-Red Light-Activatable
Paclitaxel Prodrug to Improve Selectivity toward Folate Receptor-Positive
Cancer Cells |
title_full_unstemmed | Folate-PEG Conjugates of a Far-Red Light-Activatable
Paclitaxel Prodrug to Improve Selectivity toward Folate Receptor-Positive
Cancer Cells |
title_short | Folate-PEG Conjugates of a Far-Red Light-Activatable
Paclitaxel Prodrug to Improve Selectivity toward Folate Receptor-Positive
Cancer Cells |
title_sort | folate-peg conjugates of a far-red light-activatable
paclitaxel prodrug to improve selectivity toward folate receptor-positive
cancer cells |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5664141/ https://www.ncbi.nlm.nih.gov/pubmed/29104951 http://dx.doi.org/10.1021/acsomega.7b01105 |
work_keys_str_mv | AT thapapritam folatepegconjugatesofafarredlightactivatablepaclitaxelprodrugtoimproveselectivitytowardfolatereceptorpositivecancercells AT limengjie folatepegconjugatesofafarredlightactivatablepaclitaxelprodrugtoimproveselectivitytowardfolatereceptorpositivecancercells AT karkiradha folatepegconjugatesofafarredlightactivatablepaclitaxelprodrugtoimproveselectivitytowardfolatereceptorpositivecancercells AT biomoses folatepegconjugatesofafarredlightactivatablepaclitaxelprodrugtoimproveselectivitytowardfolatereceptorpositivecancercells AT rajaputrapallavi folatepegconjugatesofafarredlightactivatablepaclitaxelprodrugtoimproveselectivitytowardfolatereceptorpositivecancercells AT nkepanggregory folatepegconjugatesofafarredlightactivatablepaclitaxelprodrugtoimproveselectivitytowardfolatereceptorpositivecancercells AT woosukyung folatepegconjugatesofafarredlightactivatablepaclitaxelprodrugtoimproveselectivitytowardfolatereceptorpositivecancercells AT youyoungjae folatepegconjugatesofafarredlightactivatablepaclitaxelprodrugtoimproveselectivitytowardfolatereceptorpositivecancercells |